Chemotherapy Induced Peripheral Neuropathy Pipeline

DelveInsight’s, “Chemotherapy Induced Peripheral Neuropathy (CIPN) - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Chemotherapy Induced Peripheral Neuropathy (CIPN): Understanding

Chemotherapy Induced Peripheral Neuropathy (CIPN): Overview

Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and complex side effect of cancer treatment, particularly with common chemotherapy drugs. It can arise during treatment, leading to dose reductions or early cessation, potentially affecting treatment effectiveness and survival outcomes. While acute CIPN often resolves after chemotherapy, in some cases, it can persist or emerge later, causing long-term symptoms. The prevalence of CIPN remains high for months after treatment, varying with the type of chemotherapy used and patient-specific factors. Despite improvements in cancer survival rates, CIPN remains a significant challenge for both patients and healthcare providers. The impact on patients' quality of life can be profound, as symptoms like pain, tingling, and numbness affect daily functioning. Moreover, the lack of effective treatments for CIPN further complicates management, making prevention and early intervention critical.

 

Symptoms of chemotherapy-induced peripheral neuropathy (CIPN) can vary depending on the nerves affected. Common signs include tingling or ""pins and needles,"" pain (which may be severe, burning, or intermittent), decreased sensation, and increased sensitivity to touch, temperature, or pressure. Muscle weakness is also common. These symptoms can develop hours to days after chemotherapy and may persist or worsen over weeks to months, especially with additional treatment cycles. It’s important to notify your care team if symptoms arise, as early intervention can help prevent worsening and improve management. Your oncologist can diagnose CIPN through symptom assessment and physical examination.

 

The pathophysiology of chemotherapy-induced peripheral neuropathy (CIPN) is multifactorial, involving a range of mechanisms triggered by chemotherapy drugs. These include mitochondrial damage, oxidative stress, disruption of microtubules, and damage to the myelin sheath. Platinum-based drugs like cisplatin, oxaliplatin, and carboplatin induce CIPN by causing neuroinflammation, altering ion channel activity, and affecting nerve function through DNA damage and mitochondrial dysfunction. Oxaliplatin, for example, induces cold neurotoxicity and alters chemokine levels, exacerbating neuropathy. Similarly, vinca alkaloids, taxanes, and protease inhibitors such as bortezomib trigger neuroinflammation and disrupt neuron excitability through ion channel changes, microtubule inhibition, and mitochondrial damage. These processes lead to peripheral nerve degeneration, contributing to the development of CIPN. Further studies are needed to fully understand these mechanisms and to develop effective prevention and treatment strategies. 

 

Treatment for chemotherapy-induced peripheral neuropathy (CIPN) involves various approaches targeting different mechanisms of the condition. Ion channel-target therapies, such as lidocaine, Gabapentin, and Pregabalin, have shown promise in alleviating symptoms by modulating nerve excitability. Anti-inflammatory treatments focusing on cytokines like TNF-α and IL-6 have demonstrated potential in pre-clinical studies, though further validation is needed. Neurotransmitter-based therapies, such as Duloxetine, are currently recommended for pain management in CIPN, while antioxidants like Mangafodipir and Calmangafodipir have shown preliminary benefits but are limited by toxicity concerns. Other options, including cannabinoids, glutamine, and topical treatments, have been explored, with varying degrees of success. Non-pharmacological interventions like massage, acupuncture, and physical therapy have also proven beneficial, although more research is required to establish effective and consistent treatments.

 

"Chemotherapy Induced Peripheral Neuropathy (CIPN)- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Peripheral Neuropathy (CIPN) treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Peripheral Neuropathy (CIPN) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Peripheral Neuropathy (CIPN) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Get More Insights into the Report @ Chemotherapy-Induced Peripheral Neuropathy Treatment Market

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Peripheral Neuropathy (CIPN) R&D. The therapies under development are focused on novel approaches to treat/improve Chemotherapy Induced Peripheral Neuropathy (CIPN).

 

Chemotherapy Induced Peripheral Neuropathy (CIPN) Emerging Drugs Chapters

This segment of the Chemotherapy Induced Peripheral Neuropathy (CIPN) report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Chemotherapy Induced Peripheral Neuropathy (CIPN) Emerging Drugs

• Capsaicin: Grünenthal GmbH

Capsaicin (QUTENZA) is a specially formulated topical system that delivers prescription-strength capsaicin directly to the skin during an in-office procedure. This way, it can reversibly desensitise and defunctionalise the TRPV1 (Transient Receptor Potential Vanilloid 1) receptor, which plays a critical role in pain signalling. QUTENZA administered as a single localised procedure can provide sustained pain relief that lasts for up to three months. It has no known drug-drug interactions. The most common adverse reactions include application site reactions, such as erythema, pain, and pruritus. Currently, the drug is in Phase III stage of its development for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN).

 

• ATX01: AlgoTherapeutix

ATX01 targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channels. It has been designed to provide targeted relief from excruciating pain in the feet and hands of patients suffering from Chemotherapy-Induced Peripheral Neuropathy (CIPN). ATX01 has wide potential applicability beyond CIPN, in other diseases where peripheral neuropathic pain is a major issue. By applying the ATX01 hydrogel to the skin, the active ingredient is locally delivered to the nerve endings where pain signals originate and propagate alongside the neurons to the central nervous system. This method of application is especially relevant to CIPN which involves localized pain. Topical administration also minimizes systemic toxicity and drug interactions through limited systemic exposure, which is particularly important in patients exposed to chemotherapy. Currently, the drug is in Phase II stage of its development for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN).

For More Insights into the Report @ Chemotherapy-Induced Peripheral Neuropathy Prevalence

 

Chemotherapy Induced Peripheral Neuropathy (CIPN): Therapeutic Assessment

This segment of the report provides insights about the different Chemotherapy Induced Peripheral Neuropathy (CIPN) drugs segregated based on following parameters that define the scope of the report, such as:

 

Major  Players in Chemotherapy Induced Peripheral Neuropathy (CIPN)

There are approx. 4+ key companies which are developing the therapies for Chemotherapy Induced Peripheral Neuropathy (CIPN). The companies which have their Chemotherapy Induced Peripheral Neuropathy (CIPN) drug candidates in the most advanced stage, i.e. Phase III include, Grünenthal GmbH.

 

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Chemotherapy Induced Peripheral Neuropathy (CIPN): Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Peripheral Neuropathy (CIPN) therapeutic drugs key players involved in developing key drugs. 

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Peripheral Neuropathy (CIPN) drugs.

 

Chemotherapy Induced Peripheral Neuropathy (CIPN) Report Insights

• Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Chemotherapy Induced Peripheral Neuropathy (CIPN) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chemotherapy Induced Peripheral Neuropathy (CIPN) drugs?
• How many Chemotherapy Induced Peripheral Neuropathy (CIPN) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy Induced Peripheral Neuropathy (CIPN) therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Chemotherapy Induced Peripheral Neuropathy (CIPN) and their status?
• What are the key designations that have been granted to the emerging drugs?

Stay updated with us for Recent Articles @ New DelveInsight Blogs